Laurus Labs: Brokerages Bullish as CDMO Segment Drives Growth

Laurus Labs has witnessed a stellar 30% surge in its share price over the last two months, fueled by a strategic pivot toward high-value segments. As the company transitions from traditional therapies to a dominant Contract Development and Manufacturing Organisation (CDMO) model, analysts are increasingly optimistic about its long-term earnings potential.

Strategic Shift from ARV to High-Value CDMO

Laurus Labs is undergoing a significant structural transformation to de-risk its revenue streams. Six years ago, the company was heavily reliant on antiretroviral (ARV) therapies, which accounted for 67% of its business. Today, that contribution has plummeted to approximately 41%, allowing the company to focus on more lucrative territories.

The star performer is the CDMO segment, which has grown from just 13% of total revenue six years ago to over 30% in FY26. This segment reported a massive 36% year-on-year growth, reaching ₹2,080 crore. This surge is attributed to the commercialization of novel molecules and increased outsourcing demand from global pharmaceutical giants. Market experts predict that the CDMO segment will contribute 50% of total revenue by FY30.

Margin Expansion and Operating Leverage

A key highlight of Laurus Labs' recent performance is the significant improvement in profitability. The company's EBITDA margin expanded by 670 basis points year-on-year to reach 26.8%. This expansion is a direct result of improved operating leverage and a more favorable product mix.

While management intends to sustain these margins, they have noted that future trends will be sensitive to volatility in raw material prices. However, the shift toward higher-margin development projects and commercialized molecules provides a strong cushion for the company's bottom line.

Aggressive ₹3,000-Crore Capex Plan

To sustain this momentum, Laurus Labs has outlined a massive capital expenditure plan of ₹3,000 crore over the next two years. Notably, over 90% of this capital is earmarked for expanding mid and large-scale manufacturing capacities.

Key investment areas include:

  • CDMO and Advanced Therapies: Scaling capacity for peptides, fermentation, and advanced therapeutic modules.
  • Greenfield Projects: The development of 'Unit 7' with over 2,000 cubic meters of reactor capacity.
  • New Commercial Blocks: A second commercial block is slated for validation by the September 2026 quarter.
  • Diversification: Expansion into non-pharma sectors like animal health and crop science. While these currently sit at a base of ₹150 crore, Motilal Oswal (MOFSL) expects them to scale beyond ₹1,000 crore in the future.

Analyst Outlook and Earnings Projections

Reflecting this confidence, Motilal Oswal Financial Services (MOFSL) has maintained a 'BUY' rating on the stock. The brokerage has revised its earnings estimates upward, raising FY27 estimates by 8% and FY28 estimates by 6%. This bullish stance is supported by the projected 22% annual growth in the CDMO segment between FY26 and FY28.

Key Takeaways

  • Revenue Pivot: The CDMO segment is set to become the primary driver, expected to reach 50% of total revenue by FY30.
  • Profitability Boost: EBITDA margins jumped 670 basis points to 26.8% due to better operating leverage and product mix.
  • Growth Investment: A ₹3,000-crore capex plan is underway to expand manufacturing capacities in CDMO, fermentation, and animal health.